Rofecoxib

FLINT COOPER HIRES NATIONALLY RECOGNIZED LEADER TRENT MIRACLE AS PARTNER TO LEAD ITS MASS TORTS PRACTICE

Retrieved on: 
Wednesday, September 20, 2023

EDWARDSVILLE, Ill., Sept. 20, 2023 /PRNewswire/ -- Flint Cooper is pleased to announce that Trent Miracle has joined the firm.

Key Points: 
  • EDWARDSVILLE, Ill., Sept. 20, 2023 /PRNewswire/ -- Flint Cooper is pleased to announce that Trent Miracle has joined the firm.
  • Miracle will serve as the managing member of the firm's mass torts practice.
  • At Flint Cooper, Miracle and his experienced team of professionals will litigate the firm's mass tort cases, as well as manage the strategic direction of the practice.
  • He is an experienced litigator in high-profile cases and will be taking our mass torts practice to the next level," said Ethan Flint, co-managing member of Flint Cooper.

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Retrieved on: 
Friday, November 11, 2022

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.

Key Points: 
  • Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.
  • These patients are often left with the inadequate options of living with pain, or resorting to opioids for pain relief.
  • Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs, Dr. Boice added.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005054/en/

EpiVario Appoints New Scientific Advisory Board Members and Expands Operations

Retrieved on: 
Tuesday, October 11, 2022

PHILADELPHIA, Oct. 11, 2022 /PRNewswire/ -- EpiVario, a biotech company developing novel therapeutics for memory-related psychiatric disorders, today announced that Anthony Ford-Hutchinson, PhD, and Paul Kenny, PhD, have been appointed to the Company's Scientific Advisory Board (SAB). They each bring deep industry and scientific experience that will help further guide EpiVario on the translation of its core discoveries through research into development, and future commercialization.

Key Points: 
  • "We are thrilled to welcome Dr. Ford-Hutchinson and Dr. Kenny to our Scientific Advisory Board," said Thomas Kim, President and CEO of EpiVario.
  • Currently, he serves as a board member or scientific advisor to various startup companies, corporations, and private foundations.
  • "I am excited to join EpiVario's Scientific Advisory Board, to help drive translation and development of its exciting pipeline that may offer new therapeutic options to patients in need."
  • Along with the new appointments to its SAB, EpiVario is expanding its operations having secured additional funding from angel investors.

Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)

Retrieved on: 
Tuesday, June 14, 2022

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Key Points: 
  • Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
  • Previously marketed as VIOXX, rofecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile in multiple indications, including acute migraine.
  • Tremeau expects that the development program for TRM-201 will include one Phase III acute efficacy and safety study in migraine.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.

BriOri BioTech Inc. Granted Patent for Topical Formulation of Vioxx

Retrieved on: 
Wednesday, March 9, 2022

BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces its patent for Topical Compositions Containing Rofecoxib (Vioxx) and Methods of Making and Using the Same was issued on March 1, 2022.

Key Points: 
  • BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces its patent for Topical Compositions Containing Rofecoxib (Vioxx) and Methods of Making and Using the Same was issued on March 1, 2022.
  • With more years of experience with NSAIDs and topical NSAIDs than any other private company and proven success in several development and commercialization arcs, the team at BriOri BioTech is working to repurpose oral NSAIDS to topical formulations.
  • These findings include:
    Im thrilled to be granted a patent for the topical formulation of rofecoxib (Vioxx), a strong long-lasting COX-2 specific NSAID, so we can bring the millions suffering from osteoarthritis safe and effective relief, concludes Register.
  • BriOri BioTech is developing a platform topical chemistry that will allow for a pipeline of opiate-free topical pain medications.

Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

Retrieved on: 
Wednesday, August 4, 2021

Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.

Key Points: 
  • Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.
  • ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.
  • ELYXYB is an oral solution dosage form which makes it convenient for patients to take it immediately upon emergence of migraine attacks.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

New Real-World Data Support Long-Term Efficacy and Safety Profile of MAVENCLAD®

Retrieved on: 
Thursday, September 12, 2019

Merck, a leading science and technology company, today announced the presentation of new data for MAVENCLAD (cladribine tablets), which further characterise the long-term efficacy and safety profile.

Key Points: 
  • Merck, a leading science and technology company, today announced the presentation of new data for MAVENCLAD (cladribine tablets), which further characterise the long-term efficacy and safety profile.
  • Our commitment to further understand the long-term efficacy and safety of MAVENCLAD goes beyond the safety profile seen in its clinical development programme, which includes up to 10 years of safety follow-up in some patients, said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck.
  • In addition, final results ( P1390 ) from the PREMIERE safety registry allowed for a thorough characterisation of the long-term safety profile of MAVENCLAD and showed no new safety findings.
  • Furthermore, post-marketing data in the first 8,419 patients treated with MAVENCLAD worldwide were consistent with the safety profile seen in the MAVENCLAD clinical development programme, with no increase in incidence of adverse events from original clinical programme findings.